{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:05Z","timestamp":1791357245427,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.euroneuro.2015.01.006","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T17:45:21Z","timestamp":1421343921000},"page":"531-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization"],"prefix":"10.1016","volume":"25","author":[{"given":"Chris A.","family":"Oosterhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"El Mansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.euroneuro.2015.01.006_bib1","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J.Med. Chem."},{"issue":"8","key":"10.1016\/j.euroneuro.2015.01.006_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/syn.20263","article-title":"The acute and chronic administration of the 5-HT(2B\/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study","volume":"59","author":"Blackburn","year":"2006","journal-title":"Synapse"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2015.01.006_bib3","first-page":"60","article-title":"Frequency-dependence of serotonin autoreceptor but not alpha 2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices","volume":"339","author":"Blier","year":"1989","journal-title":"Arch. Pharmacol."},{"issue":"Suppl. 8","key":"10.1016\/j.euroneuro.2015.01.006_bib4","first-page":"S30","article-title":"Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety","volume":"66","author":"Blier","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.006_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JCP.0b013e31823f880a","article-title":"Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia","volume":"32","author":"Buchanan","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2015.01.006_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/0091270009344855","article-title":"Exposure\u2013response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation","volume":"49","author":"Chapel","year":"2009","journal-title":"J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.01.006_bib7","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1523\/JNEUROSCI.06-10-02796.1986","article-title":"In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals","volume":"6","author":"Chaput","year":"1986","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/npp.2012.140","article-title":"Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain","volume":"38","author":"Chenu","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.euroneuro.2015.01.006_bib9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1523\/JNEUROSCI.03-08-01607.1983","article-title":"Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons","volume":"3","author":"Chiodo","year":"1983","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.006_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0006-8993(88)90197-7","article-title":"Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. II. Receptors mediating the effect of synaptically released norepinephrine","volume":"475","author":"Curet","year":"1988","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.01.006_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.biopsych.2006.05.015","article-title":"Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain","volume":"61","author":"Dremencov","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.006_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-015-3870-9","article-title":"Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain","author":"El Mansari","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.006_bib13","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1523\/JNEUROSCI.21-13-04915.2001","article-title":"Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons","volume":"21","author":"Floresco","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","article-title":"Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms","volume":"204","author":"Fr\u00e5nberg","year":"2009","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.euroneuro.2015.01.006_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/syn.21551","article-title":"Involvement of 5-HT2A receptor and \u03b12-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow","volume":"66","author":"Fr\u00e5nberg","year":"2012","journal-title":"Synapse (New York, N.Y.)"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","article-title":"Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia","volume":"196","author":"Fr\u00e5nberg","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2015.01.006_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2013.09.050","article-title":"Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism","volume":"257","author":"Gao","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","article-title":"Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain","volume":"19","author":"Ghanbari","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.006_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-2236(96)10064-3","article-title":"Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs","volume":"20","author":"Grace","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2015.01.006_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0306-4522(83)90135-5","article-title":"Intracellular and extracellular electrophysiology of nigral dopaminergic neurons \u2013 1. Identification and characterization","volume":"10","author":"Grace","year":"1983","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.euroneuro.2015.01.006_bib21","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1523\/JNEUROSCI.04-11-02877.1984","article-title":"The control of firing pattern in nigral dopamine neurons: burst firing","volume":"4","author":"Grace","year":"1984","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(25)12944-3","article-title":"Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain","volume":"277","author":"Haddjeri","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0165-0327(98)00223-7","article-title":"Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission","volume":"51","author":"Haddjeri","year":"1998","journal-title":"J. Affect. Disord."},{"issue":"23","key":"10.1016\/j.euroneuro.2015.01.006_bib24","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1523\/JNEUROSCI.18-23-10150.1998","article-title":"Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors","volume":"18","author":"Haddjeri","year":"1998","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0893-133X(96)00019-X","article-title":"Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic","volume":"15","author":"Jones-Humble","year":"1996","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0b013e3181d35d6b","article-title":"Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia","volume":"30","author":"Kane","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2015.01.006_bib28","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1177\/0269881110376684","article-title":"Attenuation of chronic mild stress-induced \u201canhedonia\u201d by asenapine is not associated with a \u201chedonic\u201d profile in intracranial self-stimulation","volume":"25","author":"Marston","year":"2011","journal-title":"J. Psychopharmacol. (Oxf., Engl.)"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.01.006_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","article-title":"Asenapine effects in animal models of psychosis and cognitive function","volume":"206","author":"Marston","year":"2009","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jad.2013.04.025","article-title":"DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data","volume":"150","author":"McIntyre","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbr.2010.05.043","article-title":"Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat","volume":"214","author":"McLean","year":"2010","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.euroneuro.2015.01.006_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.01.006_bib33","unstructured":"Oosterhof, N.N., Oosterhof, C.A., 2013. BurstiDAtor: a lightweight discharge analysis program for neural extracellular single unit recordings. Available from: \u3008www.github.com\/nno\/burstiDAtor\u3009."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0031-6997(24)01417-0","article-title":"Autoregulation of serotonin neurons: role in antidepressant drug action","volume":"51","author":"Pi\u00f1eyro","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"5 Pt 2","key":"10.1016\/j.euroneuro.2015.01.006_bib35","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1523\/JNEUROSCI.14-05-03036.1994","article-title":"Desensitization of the neuronal 5-HT carrier following its long-term blockade","volume":"14","author":"Pi\u00f1eyro","year":"1994","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.01.006_bib36","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0014-4886(73)90290-2","article-title":"Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires","volume":"41","author":"Ranck","year":"1973","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.01.006_bib38","first-page":"196","article-title":"Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study","volume":"45","author":"Schoemaker","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.006_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J. Psychopharmacol. (Oxf., Engl.)"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.01.006_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0014-2999(95)00260-R","article-title":"Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat","volume":"281","author":"Skarsfeldt","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.01.006_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0893-133X(94)00130-R","article-title":"Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons","volume":"14","author":"Stockton","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.01.006_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(01)03121-3","article-title":"Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons","volume":"922","author":"Szabo","year":"2001","journal-title":"Brain Res."},{"issue":"13","key":"10.1016\/j.euroneuro.2015.01.006_bib44","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1517\/14656566.2012.712114","article-title":"Iloperidone, asenapine and lurasidone: a primer on their current status","volume":"13","author":"Tarazi","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2015.01.006_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1017\/S1461145709990599","article-title":"Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway","volume":"13","author":"Valenti","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.006_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0006-8993(83)90011-2","article-title":"Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices","volume":"289","author":"Vandermaelen","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2015.01.006_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0014-2999(85)90222-5","article-title":"The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol","volume":"110","author":"Vogelsang","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.01.006_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(98)00711-0","article-title":"Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain","volume":"361","author":"Westerink","year":"1998","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T23:20:11Z","timestamp":1747437611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0924977X15000073"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.01.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}